VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

BACKGROUND Although the influence of VKORC1 and CYP2C9 polymorphisms on warfarin response has been studied, variability in dose explained by CYP2C9 and VKORC1 is lower among African-Americans compared with European-Americans. This has lead investigators to hypothesize that assessment of VKORC1 haplotypes may help capture a greater proportion of the variability in dose for this under-represented group. However, the inadequate representation of African-Americans and the assessment of a few VKORC1 polymorphisms have hindered this effort. METHODS To determine if VKORC1 haplotypes or haplotype groups explain a higher variability in warfarin dose, we comprehensively assessed VKORC1 polymorphisms in 273 African-Americans and 302 European-Americans. The influence of VKORC1 polymorphisms, race-specific haplotypes and haplotype groups on warfarin dose was evaluated in race-stratified multivariable analyses after accounting for CYP2C9 (*2, *3, *5, *6 and *11) and clinical covariates. RESULTS VKORC1 explained 18% (30% with CYP2C9) variability in warfarin dose among European-Americans and 5% (8% with CYP2C9) among African-Americans. Four common haplotypes in European-Americans and twelve in African-Americans were identified. In each race VKORC1 haplotypes emerged into two groups: low-dose (Group A) and high-dose (Group B). African-Americans had a lower frequency of Group A haplotype (10.6%) compared with European-Americans (35%, p < 0.0001).The variability in dose explained by VKORC1 haplotype or haplotype groups was similar to that of a single informative polymorphism. CONCLUSIONS Our findings support the use of CYP2C9, VKORC1 polymorphisms (rs9934438 or rs9923231) and clinical covariates to predict warfarin dose in both African- and European-Americans. A uniform set of common polymorphisms in CYP2C9 and VKORC1, and limited clinical covariates can be used to improve warfarin dose prediction for a racially diverse population.

[1]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[2]  C. Thorn,et al.  Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. , 2007, Pharmacogenomics.

[3]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[4]  A. Hacker,et al.  U/S: A Statistical Portrait of the American People , 1983 .

[5]  D. Conrad,et al.  A worldwide survey of haplotype variation and linkage disequilibrium in the human genome , 2006, Nature Genetics.

[6]  Larisa H Cavallari,et al.  Factors influencing warfarin dose requirements in African-Americans. , 2007, Pharmacogenomics.

[7]  G. Mcgwin,et al.  Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.

[8]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[9]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[10]  M. Rieder,et al.  Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population , 2005, Pharmacogenetics and genomics.

[11]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[12]  Zhenya Shen,et al.  Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.

[13]  C. Thorn,et al.  Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans , 2008, The Pharmacogenomics Journal.

[14]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[15]  Yusheng Zhu,et al.  Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. , 2007, Clinical chemistry.

[16]  D. Schaid.  Evaluating associations of haplotypes with traits , 2004, Genetic epidemiology.

[17]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[18]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[19]  N. Limdi,et al.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. , 2008, Pharmacogenomics.

[20]  J. Hambleton,et al.  The Influence of Ethnicity on Warfarin Dosage Requirement , 2005, The Annals of pharmacotherapy.

[21]  Hee-Jin Kim,et al.  Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. , 2007, Pharmacogenomics.

[22]  D. Allison,et al.  Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. , 2006, Blood cells, molecules & diseases.

[23]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[24]  A. Zwinderman,et al.  Estimation of Multilocus Haplotype Effects Using Weighted Penalised Log‐Likelihood: Analysis of Five Sequence Variations at the Cholesteryl Ester Transfer Protein Gene Locus , 2003, Annals of human genetics.

[25]  Dana C Crawford,et al.  Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. , 2004, American journal of human genetics.

[26]  A. Egberts,et al.  VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement , 2007, Clinical pharmacology and therapeutics.

[27]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[28]  B. Horne,et al.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[29]  M. Pirmohamed,et al.  Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.

[30]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[31]  Ingrid Glurich,et al.  Evaluation of Genetic Factors for Warfarin Dose Prediction , 2007, Clinical Medicine & Research.

[32]  C. Thorn,et al.  Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.

[33]  Tom Schalekamp,et al.  VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation , 2006, Clinical pharmacology and therapeutics.

[34]  J. Goldstein,et al.  Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. , 2007, Personalized medicine.

[35]  Y. Kokubo,et al.  Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. , 2007, Thrombosis research.

[36]  T. Lindahl,et al.  Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records , 2006, Journal of thrombosis and haemostasis : JTH.

[37]  T. Kuffner,et al.  HLA class II and TNF genes in African Americans from the Southeastern United States: regional differences in allele frequencies. , 2003, Human immunology.

[38]  Ling-Zhi Wang,et al.  A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 , 2006, Clinical pharmacology and therapeutics.

[39]  G. Novelli,et al.  Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. , 2007, Pharmacogenomics.

[40]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[41]  B. Goh,et al.  Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population , 2006, Clinical pharmacology and therapeutics.

[42]  E. Thompson,et al.  Performing the exact test of Hardy-Weinberg proportion for multiple alleles. , 1992, Biometrics.

[43]  Alan H B Wu,et al.  Use of genetic and nongenetic factors in warfarin dosing algorithms. , 2007, Pharmacogenomics.

[44]  R. Hudson,et al.  Adjusting the focus on human variation. , 2000, Trends in genetics : TIG.

[45]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.